Loading…
This event has ended. Visit the official site or create your own event on Sched.
View analytic
Tuesday, September 19 • 9:15am - 10:30am
The Promise and Perils of Ketamine in Psychiatric Practice

Sign up or log in to save this to your schedule and see who's attending!

Ketamine is a U.S. Food and Drug Administration-approved anesthetic agent, which is increasingly being used “off label” for various psychiatric conditions. This session will educate practicing clinicians about the use of ketamine for psychiatric disorders, especially its use in treatment-resistant mood disorders and posttraumatic stress disorder. An overview of data from controlled research studies and experience in clinical practice settings will be presented. Important unresolved issues will be examined, including patient selection, treatment implementation (dose optimization, route of administration, maintenance treatment), and risk management, with the goal of providing a balanced view of a controversial “off-label” therapy.


Speakers
avatar for Sanjay J. Mathew, MD

Sanjay J. Mathew, MD

Johnson Family Chair for Research in Psychiatry; Professor of Psychiatry & Behavioral Sciences, Baylor College of Medicine; Staff Clinician, Michael E. Debakey VA Medical Center, Houston, Texas | Sanjay J. Mathew, MD, is the Johnson Family Chair for Research in Psychiatry and an Associate Professor with tenure in the Menninger Department of Psychiatry and Behavioral Sciences. Dr. Mathew is also a staff psychiatrist at the Michael E. Debakey Veterans Affairs Medical Center in Houston, Texas. His research program is the recipient of federal grants and contracts from the National Institute of Mental Health and the Department of Veterans Affairs to develop novel therapies for patients with treatment-resistant depression and Post-traumatic Stress Disorder. Dr. Mathew's translational research program focuses on testing of experimental therapies for depression and anxiety, and discovering illness and treatment-related biomarkers. Much of his work has focused on glutamate modulating agents, which act as rapidly acting antidepressants. Dr. Mathew graduated from Dartmouth College with a degree in Biology, and received his medical degree from Baylor College of Medicine. Dr. Mathew completed his residency training in Psychiatry at Columbia University's College of Physicians and Surgeons and the New York State Psychiatric Institute, where he also completed a National Institute of Mental Health research fellowship. Dr. Mathew began his faculty career at the Mount Sinai School of Medicine in New York, where he directed the Mood and Anxiety Disorders Program. Dr. Mathew has directed the Baylor program since... Read More →


Tuesday September 19, 2017 9:15am - 10:30am
Hall E-2 The New Orleans Ernest N. Morial Convention Center 900 Convention Center Boulevard New Orleans, LA 70130